Bristol Myers Squibb and Johnson & Johnson have said they will stop development of their oral Factor XIa inhibitor milvexian in acute coronary syndrome after a disappointing trial result. The decision ...

KUALA LUMPUR: BMS Holdings Bhd made a lacklustre debut on the ACE Market of Bursa Malaysia today, opening below its initial public offering (IPO) price of 22 sen per share. The Johor-based building ...

KUALA LUMPUR: BMS Holdings Bhd, which is set to list on the ACE Market of Bursa Malaysia Securities on Dec 8, saw the public portion of its initial public offering (IPO) subscribed 2.40 times. The ...

FRANKFURT, Nov 3 (Reuters) - Germany's BioNTech (22UAy.DE), opens new tab on Monday lifted its 2025 revenue guidance after receiving initial payments from its new partner Bristol Myers Squibb (BMY.N), ...

Bristol-Myers Squibb Company (NYSE:BMY) is one of the cheap stocks to buy for the next 5 years. On October 2, Bristol Myers Squibb announced a development in its Alzheimer’s program: its experimental ...

BMS will acquire Orbital’s lead product OTX-201, in development for the treatment of B-cell driven autoimmune diseases, as part of the deal. Tada Images via Shutterstock.com. Bristol Myers Squibb (BMS ...

On the heels of the launch of an online direct-to-patient (DTP) program offering discounted Eliquis to certain U.S. patients, Bristol Myers Squibb is putting Sotyku at the center of its next DTP ...

More than 40 years after establishing the first U.S. pharmaceutical joint venture in China, Bristol Myers Squibb is handing over its controlling stake in the business. BMS has inked an agreement to ...

Beecher Manufacturing Services acquired BMS Manufacturing Co. in Watkins Glen, New York. The acquisition will help Ward Apparatus, another Beecher company, increase fire truck production. The ...

Bristol Myers Squibb, Board Chair of BMS and CEO Christopher Boerner, PhD, have committed the pharma giant to investing $40 billion over the next five years toward U.S. research and development (R&D), ...

Bristol Myers Squibb (BMS) plans to buy out its partner in developing the blockbuster multiple myeloma drug Abecma ® (idecabtagene vicleucel), by agreeing to acquire 2seventy bio for approximately ...

Bristol Myers Squibb stock (NYSE: BMY) has gained 7% this year, outperforming the S&P 500 which has declined 1%. BMS’s strong Q4 performance has helped drive its positive momentum. While markets ...